TABLE 2.
FSR
|
FSR/FSRmax
|
[Ca]SR (mM)
|
||||
---|---|---|---|---|---|---|
Baseline | Nadir | Baseline | Nadir | Baseline | Nadir | |
Control | 370 ± 15 | 256 ± 8 | 0.74 ± 0.03 | 0.51 ± 0.01 | 1.12 ± 0.13 | 0.42 ± 0.01 |
WT | 376 ± 47 | 270 ± 38 | 0.75 ± 0.09 | 0.54 ± 0.08 | 1.22 ± 0.25 | 0.48 ± 0.09 |
DEL | 401 ± 19 | 287 ± 14 | 0.73 ± 0.03 | 0.52 ± 0.03 | 1.08 ± 0.16 | 0.45 ± 0.05 |
R33Q | 202 ± 20*† | 128 ± 12*† | 0.47 ± 0.05*† | 0.31 ± 0.03*† | 0.37 ± 0.12*† | 0.18 ± 0.03*† |
Local intra-SR Fluo-5N signals and estimated [Ca]SR in permeabilized myocytes infected with control adenovirus and adenoviral constructs encoding WT CASQ2, DEL, and R33Q CASQ2 mutants. FSR = F − FCAFF; FSRmax= Fmax − FCAFF; and [Ca]SR = Kd(FSR)/(FSRmax − FSR), where Kd was 400 μM (2).
Significantly different if compared with control or †if compared with WT, p < 0.05, one-way ANOVA, n of blinks from 13 to 16, n of cells from 8 to 13.